Can You Take Meloxicam with Gabapentin?

Severity assessment

Moderate. The co-administration of gabapentin and meloxicam can lead to an increased risk of additive central nervous system (CNS) depression and gastrointestinal adverse effects.

Mechanism (plain English)

Gabapentin works by affecting certain chemicals and nerves in the body that are involved in seizures and pain. It can cause side effects like drowsiness, dizziness, and difficulty with coordination because it slows down brain activity. Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that reduces pain, inflammation, and fever by blocking certain enzymes (COX-1 and COX-2) that produce prostaglandins, which are chemicals that promote inflammation. While meloxicam primarily acts on inflammation, it can also affect the stomach lining and kidneys. The interaction between these two medications is not a direct chemical reaction, but rather an additive effect where the side effects of each drug can become more pronounced when taken together. Specifically, gabapentin's CNS depressant effects (drowsiness, dizziness) can be enhanced, and meloxicam's potential to cause stomach upset or kidney issues might be exacerbated, especially in vulnerable individuals.

Evidence level

Theoretical. No specific regulator-flagged interaction for this exact pair has been identified. The assessment is based on the known pharmacological profiles and potential additive side effects of each drug, as well as general warnings for drug classes.

Top regulator advisories (cite verbatim or close paraphrase)

• TGA (Australia): No pair-specific public advisory found. For gabapentin, the Australian Product Information (PI) for Neurontin (gabapentin) highlights CNS depressant effects such as somnolence and dizziness, and advises caution when co-administered with other CNS depressants. For meloxicam, the Australian PI for Mobic (meloxicam) warns of serious gastrointestinal events (bleeding, ulceration, perforation) and renal toxicity, which are common risks with NSAIDs.
• MHRA / NICE (UK): No specific guidance for this exact drug pair. The MHRA has issued warnings regarding gabapentin and pregabalin, noting a rare risk of severe respiratory depression, even without concomitant opioid medicines [1]. NICE guidelines for chronic pain management generally advise caution with polypharmacy and monitoring for adverse effects. The British National Formulary (BNF) for meloxicam lists common NSAID risks including gastrointestinal irritation and renal impairment.
• FDA / CDC (US): No specific FDA safety communication or CDC guidance for gabapentin and meloxicam in combination. The FDA prescribing information for Neurontin (gabapentin) lists somnolence and dizziness as common adverse reactions and notes potential for increased concentrations with morphine, suggesting caution with other CNS depressants [2]. The FDA prescribing information for Mobic (meloxicam) includes a boxed warning for serious cardiovascular thrombotic events and serious gastrointestinal adverse events, consistent with NSAID class effects [3].
• EMA (Europe): No specific EMA advisory for this combination. General warnings for gabapentinoids regarding CNS depression and for NSAIDs regarding gastrointestinal and renal risks would apply.

Clinical risk factors that elevate the danger

Patients who are elderly, have pre-existing kidney impairment, a history of gastrointestinal ulcers or bleeding, or who are taking other medications that cause drowsiness (e.g., opioids, benzodiazepines, alcohol) are at higher risk. Individuals with compromised respiratory function or those taking other nephrotoxic drugs may also experience elevated risks.

What a patient should be told

• You might feel more drowsy, dizzy, or less coordinated than usual when taking gabapentin and meloxicam together. Be careful when driving or operating machinery until you know how these medicines affect you.
• Watch out for signs of stomach problems like new or worsening stomach pain, black or tarry stools, or vomiting blood. Also, be aware of changes in urination, swelling in your ankles, or unusual tiredness, which could indicate kidney issues.
• Do not stop taking either medication suddenly without talking to your doctor or pharmacist, as this can lead to withdrawal symptoms or worsening of your underlying condition.
• If you experience severe dizziness, extreme drowsiness, difficulty breathing, severe stomach pain, or any signs of bleeding, seek urgent medical attention immediately.
• Always discuss all your medications, including over-the-counter drugs and supplements, with your prescriber or pharmacist to ensure the safest treatment plan for you.

Top 3 sources (with full citation)

1. Medicines and Healthcare products Regulatory Agency (MHRA). Gabapentin (Neurontin): risk of severe respiratory depression. GOV.UK. Published October 26, 2017. https://www.gov.uk/drug-safety-update/gabapentin-neurontin-risk-of-severe-respiratory-depression
2. U.S. Food and Drug Administration (FDA). NEURONTIN (gabapentin) capsules, tablets, oral solution prescribing information. Revised October 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
3. U.S. Food and Drug Administration (FDA). MOBIC (meloxicam tablets) prescribing information. Revised April 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020938s028lbl.pdf

Notes for the reviewing pharmacist

While direct, specific drug-drug interaction studies between gabapentin and meloxicam are not commonly cited as major, the potential for additive adverse effects is a key consideration. Gabapentin's CNS depressant properties (somnolence, dizziness, ataxia) can be exacerbated by other sedating agents, though meloxicam is not typically classified as a primary CNS depressant. However, the general debilitation or reduced alertness from pain and inflammation, for which both drugs might be prescribed, could indirectly heighten the perceived CNS effects. Meloxicam, as an NSAID, carries inherent risks of gastrointestinal irritation, ulceration, bleeding, and renal impairment. These risks are dose-dependent and can be influenced by patient comorbidities (e.g., advanced age, renal dysfunction, history of GI disease) and concomitant medications (e.g., anticoagulants, corticosteroids). Pharmacists should counsel patients on monitoring for signs of increased sedation, gastrointestinal distress, and changes in renal function, especially in at-risk populations. The lack of specific regulatory advisories for this pair emphasizes the need for clinical judgment based on individual patient profiles and the known pharmacology of each agent. The study on antinociceptive interactions in rats suggests potential synergistic pain relief, but this does not negate the importance of managing potential additive side effects in humans.

Source metadata JSON